Diarrhea in Crohn's disease: Investigating the role of the ileal hormone fibroblast growth factor 19

Journal of Crohn's and Colitis

Volumn 9, Issue 2, 2015, Pages 125-131

  Nolan, Jonathan D ^a   Johnston, Ian M ^a   Pattni, Sanjeev S ^a   Dew, Tracy ^b   Orchard, Timothy R ^a   Walters, Julian R F ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Bile acid diarrhea; Bile acid malabsorption; Crohn's disease; FGF19; Ileitis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBROBLAST GROWTH FACTOR 19; GASTROINTESTINAL HORMONE; FGF19 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR;

ADULT; AGED; ARTICLE; BRISTOL STOOL FORM SCALE; CONTROLLED STUDY; CORRELATIONAL STUDY; CROHN DISEASE; DIARRHEA; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE ASSOCIATION; DISEASE SEVERITY; FECES ANALYSIS; FEMALE; HARVEY BRADSHAW INDEX; HUMAN; ILEUM; ILEUM RESECTION; INTESTINE FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BIOPSY; COMPLICATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY;

ADULT; AGED; BIOMARKERS; BIOPSY; CROHN DISEASE; DIARRHEA; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; ILEUM; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84953885227     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jju022     Document Type: Article

References (33)

1. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980;1:514
2. Sandle GI, Higgs N, Crowe P, et al. Cellular basis for defective electrolyte transport in inflamed human colon. Gastroenterology 1990;99:97-105
3. Mekjian HS, Phillips SF, Hofmann AF. Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man. J Clin Invest 1971;50:1569-77
4. Vantrappen G, Ghoos Y, Rutgeerts P, et al. Bile acid studies in uncomplicated Crohn's disease. Gut 1977;18:730-5
5. Jung D, Fantin AC, Scheurer U, et al. Human ileal bile acid transporter gene ASBT [SLC10A2] is transactivated by the glucocorticoid receptor. Gut 2004;53:78-84
6. Neimark E, Chen F, Li X, et al. c-Fos is a critical mediator of inflammatory-mediated repression of the apical sodium-dependent bile acid transporter. Gastroenterology 2006;131:554-67
7. Vijayvargiya P, Camilleri M, Shin A, et al. Methods for diagnosis of bile acid malabsorption in clinical practice. Clin Gastroenterol Hepatol 2013;11:1232-9
8. Boyd GS, Merrick MV, Monks R, et al. Se-75-labeled bile acid analogs, new radiopharmaceuticals for investigating the enterohepatic circulation. J Nucl Med 1981;22:720-5
9. Smith MJ, Cherian P, Raju GS, et al. Bile acid malabsorption in persistent diarrhoea. J R Coll Physicians Lond 2000;34:448-51
10. Nyhlin H, Merrick MV, Eastwood MA. Bile acid malabsorption in Crohn's disease and indications for its assessment using SeHCAT. Gut 1994;35: 90-3
11. Beigel F, Teich N, Howaldt S, et al. Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: a randomized, double-blind, placebo-controlled study. J Crohns Colitis 2014;8:147-19
12. Brydon WG, Nyhlin H, Eastwood MA, et al. Serum 7 alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine [SeHCAT] whole body retention in the assessment of bile acid induced diarrhoea. Eur J Gastroenterol Hepatol 1996;8:117-23
13. Gothe F, Beigel F, Rust C, et al. Bile acid malabsorption assessed by 7 alpha-hydroxy-4-cholesten-3-one in pediatric inflammatory bowel disease: correlation to clinical and laboratory findings. J Crohns Colitis 2014;8:1072-8
14. Zhang JH, Nolan JD, Kennie SL, et al. Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids. Am J Physiol Gastrointest Liver Physiol 2013;304:G940-8
15. Lundasen T, Galman C, Angelin B, et al. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 2006;260:530-6
16. Meyer-Gerspach AC, Steinert RE, Keller S, et al. Effects of chenodeoxycholic acid on the secretion of gut peptides and fibroblast growth factors in healthy humans. J Clin Endocrinol Metab 2013;98:3351-8
17. Walters JR, Tasleem AM, Omer OS, et al. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol 2009;7:1189-94
18. Pattni SS, Brydon WG, Dew T, et al. Fibroblast growth factor 19 and 7alpha-hydroxy-4-cholesten-3-one in the diagnosis of patients with possible bile acid diarrhea. Clin Transl Gastroenterol 2012;3:e18
19. Iwamoto J, Saito Y, Honda A, et al. Bile acid malabsorption deactivates pregnane X receptor in patients with Crohn's disease. Inflamm Bowel Dis 2013;19:1278-84
20. Lenicek M, Duricova D, Komarek V, et al. Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers. Inflamm Bowel Dis 2011;17:1322-7
21. Pattni SS, Brydon WG, Dew T, et al. Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention. Aliment Pharmacol Ther 2013;38:967-76
22. Walters JR, Johnston IM, Nolan JD, et al. The response of patients with bile acid diarrhea to the farnesoid X receptor agonist obeticholic acid. Aliment Pharmacol Ther 2015;41:54-64
23. Rutgeerts P, Ghoos Y, Vantrappen G. Kinetics of primary bile acids in patients with non-operated Crohn's disease. Eur J Clin Invest 1982;12:135-43
24. Nowicki MJ, Shneider BL, Paul JM, et al. Glucocorticoids upregulate taurocholate transport by ileal brush-border membrane. Am J Physiol 1997;273:G197-203
25. Holt JA, Luo G, Billin AN, et al. Definition of a novel growth factordependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 2003;17:1581-91
26. Vavassori P, Mencarelli A, Renga B, et al. The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol 2009;183:6251-61
27. Gadaletta RM, van Epercum KJ, Oldenburg B, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 2011;60:463-472
28. Fiorucci S, Rizzo G, Antonelli E, et al. A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther 2005;314:584-95
29. Fiorucci S, Antonelli E, Rizzo G, et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 2004;127:1497-512
30. Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid x receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013;145:574-82.e1
31. Wildenberg ME, van den Brink GR. FXR activation inhibits inflammation and preserves the intestinal barrier in IBD. Gut 2011;60:432-3
32. van Schaik FD, Gadaleta RM, Schaap FG, et al. Pharmacological activation of the bile acid nuclear farnesoid X receptor is feasible in patients with quiescent Crohn's colitis. PLoS One 2012;7:e49706
33. Nijmeijer RM, Gadaleta RM, van Mil SW, et al. Farnesoid X receptor [FXR] activation and FXR genetic variation in inflammatory bowel disease. PLoS One 2011;6:e23745